Assertio Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 6% to two-week high after Trump says deal with Iran 'over'
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Assertio Therapeutics (ASRT) Misses Q2 EPS by 32c, Revenues Miss
August 7, 2020 6:19 AM EDTAssertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of ($0.35), $0.32 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $20.62 million versus the consensus estimate of $25.33 million.
Even in what has been an unprecedented time with patient volume and elective... More
